How Oncologists Are Confronting the Cancer Drug Shortage

How Oncologists Are Confronting the Cancer Dr...

Up next

Day 5: Top Takeaways From ASCO26

Dr. Monty Pal shares highlights from the final day of ASCO26, including new research on treating anemia in myelofibrosis, advances in RAS-mutated mCRC, novel therapies for AML, and a potentially practice-changing trial in TNBC. LINK TO FULL TRANSCRIPT 

Day 4: Top Takeaways From ASCO26

Dr. Monty Pal shares highlights from Day 4 of the 2026 ASCO Annual Meeting, including a much-anticipated study in hepatocellular carcinoma, new data in non–small cell lung cancer, and a key update in the treatment of Merkel cell carcinoma. LINK TO TRANSCRIPT 

Recommended Episodes

Opioids and Cancer Pain: Patients' Needs and Access Challenges
JCO Oncology Practice Podcast

Dr. Pennell talks with Dr. Ray Page about efforts to address the opioid crisis impact onthe care of patients, and what role oncologists can play on this issue. Hello, and welcome to the ASCO Journal of Oncology Practice podcast. This is Dr. Nate Pennell, medical oncologist at the ...  Show more

Cannabis and Cannabinoids in Adults with Cancer Guideline
ASCO Guidelines

Dr. Ilana Braun and Dr. Eric Roeland join us on the ASCO Guidelines podcast to discuss the latest evidence-based recommendations on cannabis and cannabinoids in adults with cancer. They discuss nonjudgmental patient-clinician communication, the relatively narrow cancer-related in ...  Show more

Systemic Therapy for SCLC: ASCO-OH (CCO) Guideline
ASCO Guidelines

Dr. Greg Kalemkerian joins us on the ASCO Guideline Podcast to discuss the newest ASCO – Ontario Health (Cancer Care Ontario) Guideline on systemic therapy for small-cell lung cancer (SCLC). He reviews the evidence-based recommendations from the panel, including guidance on syste ...  Show more

Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2024.1
ASCO Guidelines

Dr. Jyoti Patel discusses the latest update to the stage IV NSCLC with driver alterations living guideline, specifically for patients with EGFR or ROS1 alterations. She shares the latest recommendations based on recently published evidence, such as the FLAURA2, MARIPOSA-2, and TR ...  Show more